{"id":"W4387825536","doi":"10.1016/j.annonc.2023.09.2347","title":"1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Genentech; F. Hoffmann-La Roche; Grifols; Eisai; Ipsen; Sociedad Española de Oncología Médica; BeiGene; Mirati Therapeutics; Regeneron Pharmaceuticals; Boston Pharmaceuticals; Daiichi Sankyo Europe; Gilead Sciences; Merck KGaA; Exelixis; Sanofi; Amgen; Pfizer; Takeda Pharmaceuticals International; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Discontinuation; Gastroenterology; Adverse effect; Oncology; Pharmacokinetics; Antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004119427,0.0002307951,0.0008296929,0.0003979352,0.00006654827,0.000008201127,0.00007851397,0.0001409599,0.00008105257],"category_scores_gemma":[0.00003637235,0.0001694599,0.00006968003,0.0006647126,0.0002397841,0.00008310001,0.00006556916,0.0002194756,0.000002354818],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003085904,"about_ca_system_score_gemma":0.0002149874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001996535,"about_ca_topic_score_gemma":0.00006411174,"domain_scores_codex":[0.9983276,0.0001219954,0.0005399154,0.0004176114,0.0002361155,0.0003567466],"domain_scores_gemma":[0.9987817,0.0001919733,0.0003912477,0.0002275295,0.0002701454,0.0001374432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009317193,0.002143466,0.952048,0.0008250065,0.0004276466,0.0002504065,0.002740029,0.0003281552,0.01679808,0.000009150036,0.00151228,0.01360056],"study_design_scores_gemma":[0.01616493,0.008476102,0.9629415,0.001614044,0.0001436135,0.000009874111,0.0006164391,0.001487141,0.006408134,0.000002237509,0.001865781,0.0002702196],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960843,0.001051967,0.0000385741,0.0009958008,0.00001571845,0.0007458983,0.00006071117,0.00002902241,0.0009780393],"genre_scores_gemma":[0.9917344,0.007138889,0.0002245438,0.0003405177,0.00003939162,0.00002160551,0.0001378998,0.00003286602,0.0003298512],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01333034,"threshold_uncertainty_score":0.6910373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0274594783006836,"score_gpt":0.3419865786908813,"score_spread":0.3145271003901977,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}